Subcutaneous FatPhase 2NCT07608770
A Study to Evaluate the Efficacy, Safety, and Tolerability of CBL-514 Injection for Reducing Abdominal Subcutaneous Fat
A Phase 2 study testing CBL-514 Injection and 0.9% Sodium Chloride in people with Subcutaneous Fat, run by Caliway Biopharmaceuticals Co., Ltd. at 1 site in Australia.
Trial summary
A phase 2b, randomized, placebo-controlled study with long-term re-treatment to evaluate the efficacy, safety, and tolerability of CBL-514 injection for reducing abdominal subcutaneous fat Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Subcutaneous Fat
- What is being tested?
- CBL-514 Injection and 0.9% Sodium Chloride
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 250 participants
- Where
- 1 siteAustralia
- Study dates
- 1 Jun 2026to Nov 2027
- Phase
- Phase 2
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Male or female, aged ≥ 18 years old.
- Body mass index (BMI) > 18.5 and < 30 kg/m2 and body weight ≥ 50 kg.
- CR-AFRS and PR-AFRS score: participant has Grade 3 or Grade 4 abdominal fat as assessed both by the Investigator on the CR-AFRS and by the participant on the PR-AFRS.
- Participant maintained a stable lifestyle.
- Voluntarily signs the Informed Consent Form and, in the opinion of the Investigator or delegate, is physically and mentally capable of participating in the study, and willing to adhere to study procedures.
Who cannot join
- Female participant of childbearing potential who is not willing to commit to an acceptable contraceptive method and refraining from ova donation from the time of Screening and throughout the study until 90 days after the last dose of IP, or who is currently pregnant or lactating. Fertile male participant who is not willing to commit to an acceptable contraceptive method and refraining from sperm donation from the time of the first dose of IP and throughout the study until 90 days after the last dose of IP.
- Participant was diagnosed with coagulation disorders or is receiving anticoagulant/antiplatelet therapy or medications.
- Participant has delayed wound healing or poorly controlled diabetes.
- Participant has a history of active malignancy within 3 years before Screening, or is currently being evaluated for a possible malignancy.
- Participant has a history of trypanophobia, the extreme fear of medical procedures involving injections or needles.
- Participant has a visible Panniculus (folding fat) or visible folds of skin on the abdomen in a standing position.
Show all 21Show fewer
- Participant has severe or very severe abdominal visceral fat.
- Participant has skin conditions which, in the opinion of the Investigator, would pose a risk to the participant if receiving the IP or interfere with the safety or efficacy evaluation.
- Participant has undergone the following procedures: a. Surgery that caused scar tissue at the treatment area; b. Previous history of abdominoplasty or abdominal liposuction within the treatment area; c. Aesthetic procedure for body contouring or fat reduction at the treatment area within 12 months before Screening; d. SC injection or transdermal application of medication at the treatment area within 4 weeks before Screening.
- Participant with contraindications to magnetic resonance imaging (MRI)
- Participant is on prescription or over-the-counter weight reduction medication, weight reduction programs, or taking oral or injectable GLP-1 agonists (eg, semaglutide, tirzepatide, liraglutide, etc.) within 6 months before Screening.
- Participant is undergoing long-term systemic steroid or immunosuppressive therapy
- Participant is taking or will take any medication that is a known strong inhibitor or inducer of CYP1A2 enzymes, sensitive CYP1A2 substrates, or medication with narrow therapeutic index during the study that, in the opinion of the Investigator, may affect the safety or efficacy evaluation of the IP or pose undue risk to the participant.
- Participant with history of hypersensitivity to local anesthesia (eg, lidocaine).
- Participant with known allergies or significant adverse reaction to the IP or any of its ingredients.
- Participant with liver cirrhosis or abnormal liver function test at Screening
- Participant currently on dialysis or with any renal impairment at Screening
- Participant has received any investigational product (including a device) within 3 months before Screening.
- Participant has an unstable condition (eg, psychiatric disorder, history of substance abuse within 3 years before Screening) or is otherwise thought to be unreliable or incapable of complying with the requirements of the protocol (eg, visit schedule, off-site MRI measurement).
- Participant with a known history or current diagnosis of body dysmorphic disorder or eating disorders.
- Participant has a history of vasovagal syncope.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Australia1 site, 1 recruiting
- Recruiting
Investigational Site 1
South Yarra, Victoria, 3141
About this study
Official title: A Phase 2b, Randomized, Placebo-Controlled Study With Long-term Re-Treatment to Evaluate the Efficacy, Safety, and Tolerability of CBL-514 Injection for Reducing Abdominal Subcutaneous Fat (Stage 1)
A phase 2b, randomized, placebo-controlled study with long-term re-treatment to evaluate the efficacy, safety, and tolerability of CBL-514 injection for reducing abdominal subcutaneous fat
Read the detailed description
A total of approximately 250 adult participants with Grade 3 or Grade 4 abdominal fat, as assessed by Clinician Reported-Abdominal Fat Rating Scale (CR-AFRS) and Patient Reported-Abdominal Fat Rating Scale (PR-AFRS) at baseline will be enrolled. Each participant will receive up to 4 treatments of allocated study drug administered subcutaneously to the abdomen, once every 3 weeks.
- Conditions
- Subcutaneous Fat
- Being tested
- CBL-514 Injection, 0.9% Sodium Chloride
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
CBL-514 InjectionDrug
Provided as a ready for use injectable CBL-514 solution
0.9% Sodium ChlorideDrug
Injectable 0.9% Sodium Chloride solution as placebo
| Study group | Role | What they receive |
|---|---|---|
| CBL-514 injection | Experimental | Participants will receive CBL-514 administered up to 120 mL per treatment at a 3-weeks interval for up to 4 treatments. Receives: Drug: CBL-514 Injection |
| Injectable 0.9% Sodium Chloride solution | Placebo comparator | Participants will receive 0.9% Sodium Chloride administered up to 120 mL per treatment at a 3-week interval for up to 4 treatments. Receives: Drug: 0.9% Sodium Chloride |
What is being measured
The primary outcome is the main question the study is designed to answer.
Percentage change from Baseline in abdominal fat in the CBL-514 group versus the placebo group
Measured by MRI
Measured: From baseline to 4 weeks after final treatment
Secondary outcomes (3)
Percentage change from Baseline in abdominal fat in the CBL-514 group versus the placebo group
Measured by MRI
Measured: From baseline to 12 weeks after final treatment
Percentage of participants with at least a 1-grade improvement on Clinician Reported-Abdominal Fat Rating Scale in the CBL-514 group versus the placebo group
Measured by a 5-point rating scale from Grade 1 to Grade 5 for assessing the severity of abdominal fat. Lower score indicates less abdominal fat. Higher score indicates more abdominal fat.
Measured: From baseline to 4 weeks and 12 weeks after final treatment
Percentage of participants with at least a 1-grade improvement on Patient Reported-Abdominal Fat Rating Scale in the CBL-514 group versus the placebo group
Measured by a 5-point rating scale from Grade 1 to Grade 5 for assessing the severity of abdominal fat. Lower score indicates less abdominal fat. Higher score indicates more abdominal fat.
Measured: From baseline to 4 weeks and 12 weeks after final treatment
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted27 May 2026
- Study start1 Jun 2026
- Primary completionApr 2027 (estimated)
- Study completionNov 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Subcutaneous FatStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 250 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Caliway Biopharmaceuticals Co., Ltd.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Anne Sheu, Study director, Caliway Biopharmaceuticals Co., Ltd.
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07608770
- Sponsor's protocol ID
- CBL-0206 (Stage 1)
- Status last verified
- Jun 2026
- First submitted
- 19 May 2026
- Last updated
- 20 Oct 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 20 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase 2b, Randomized, Placebo-Controlled Study With Long-term Re-Treatment to Evaluate the Efficacy, Safety, and Tolerability of CBL-514 Injection for Reducing Abdominal Subcutaneous Fat (Stage 1)
- ClinicalTrials.gov ID
- NCT07608770
- Acronym / sponsor ID
- CBL-0206 (Stage 1)
- Conditions
- Subcutaneous Fat
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 250 participants (estimated)
- Lead sponsor
- Caliway Biopharmaceuticals Co., Ltd.Industry (pharma, biotech, devices)
- Study start
- 1 Jun 2026 (actual)
- Primary completion
- Apr 2027 (estimated)
- Study completion
- Nov 2027 (estimated)
- First posted
- 27 May 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
A phase 2b, randomized, placebo-controlled study with long-term re-treatment to evaluate the efficacy, safety, and tolerability of CBL-514 injection for reducing abdominal subcutaneous fat
Detailed description
A total of approximately 250 adult participants with Grade 3 or Grade 4 abdominal fat, as assessed by Clinician Reported-Abdominal Fat Rating Scale (CR-AFRS) and Patient Reported-Abdominal Fat Rating Scale (PR-AFRS) at baseline will be enrolled. Each participant will receive up to 4 treatments of allocated study drug administered subcutaneously to the abdomen, once every 3 weeks.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (participant)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| CBL-514 injection | Experimental | Drug: CBL-514 InjectionParticipants will receive CBL-514 administered up to 120 mL per treatment at a 3-weeks interval for up to 4 treatments. |
| Injectable 0.9% Sodium Chloride solution | Placebo comparator | Drug: 0.9% Sodium ChlorideParticipants will receive 0.9% Sodium Chloride administered up to 120 mL per treatment at a 3-week interval for up to 4 treatments. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Male or female, aged ≥ 18 years old.
- Body mass index (BMI) > 18.5 and < 30 kg/m2 and body weight ≥ 50 kg.
- CR-AFRS and PR-AFRS score: participant has Grade 3 or Grade 4 abdominal fat as assessed both by the Investigator on the CR-AFRS and by the participant on the PR-AFRS.
- Participant maintained a stable lifestyle.
- Voluntarily signs the Informed Consent Form and, in the opinion of the Investigator or delegate, is physically and mentally capable of participating in the study, and willing to adhere to study procedures.
Key exclusion criteria (21 listed)
- Female participant of childbearing potential who is not willing to commit to an acceptable contraceptive method and refraining from ova donation from the time of Screening and throughout the study until 90 days after the last dose of IP, or who is currently pregnant or lactating. Fertile male participant who is not willing to commit to an acceptable contraceptive method and refraining from sperm donation from the time of the first dose of IP and throughout the study until 90 days after the last dose of IP.
- Participant was diagnosed with coagulation disorders or is receiving anticoagulant/antiplatelet therapy or medications.
- Participant has delayed wound healing or poorly controlled diabetes.
- Participant has a history of active malignancy within 3 years before Screening, or is currently being evaluated for a possible malignancy.
- Participant has a history of trypanophobia, the extreme fear of medical procedures involving injections or needles.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| CBL-514 InjectionProvided as a ready for use injectable CBL-514 solution | Drug | CBL-514 injection |
| 0.9% Sodium ChlorideInjectable 0.9% Sodium Chloride solution as placebo | Drug | Injectable 0.9% Sodium Chloride solution |
Primary outcome
Percentage change from Baseline in abdominal fat in the CBL-514 group versus the placebo group
Time frame: From baseline to 4 weeks after final treatment
Measured by MRI
3 secondary outcomes
Percentage change from Baseline in abdominal fat in the CBL-514 group versus the placebo group
Time frame: From baseline to 12 weeks after final treatment
Percentage of participants with at least a 1-grade improvement on Clinician Reported-Abdominal Fat Rating Scale in the CBL-514 group versus the placebo group
Time frame: From baseline to 4 weeks and 12 weeks after final treatment
Percentage of participants with at least a 1-grade improvement on Patient Reported-Abdominal Fat Rating Scale in the CBL-514 group versus the placebo group
Time frame: From baseline to 4 weeks and 12 weeks after final treatment
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 20 Oct 2026.
Related trials for Subcutaneous Fat
Not yet recruitingPhase 3
A Study to Evaluate the Efficacy and Safety of CBL-514 Injection for Reducing Subcutaneous Fat ( SUPREME-02 )
Subcutaneous Fat
Not yet recruitingPhase 2
A Study to Evaluate the Efficacy, Safety, and Tolerability of CBL-514 Injection for Reducing Abdominal Subcutaneous Fat
Subcutaneous Fat
RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of CBL-514 Injection for Reducing Subcutaneous Fat
Subcutaneous Fat
Not yet recruitingPhase 3
A Study to Evaluate the Maintenance of Efficacy and Long-term Safety of CBL-514 Injection for Reducing Subcutaneous Fat (Stage 1)
Subcutaneous Fat
Recruiting
Change of Adipose Tissues and Triglyceride After Bariatric Surgery or Life-style Intervention
Non-Alcoholic Fatty Liver Disease, Obesity, Morbid
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Anne Sheu study director
Caliway Biopharmaceuticals Co., Ltd.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing CBL-514 Injection and 0.9% Sodium Chloride in people with Subcutaneous Fat, run by Caliway Biopharmaceuticals Co., Ltd. at 1 site in Australia.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 21 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 20 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Australia. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Joanna Lu (+886-2-26971355 ext. 1318, cwcr@caliwaybiopharma.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Percentage change from Baseline in abdominal fat in the CBL-514 group versus the placebo group (time frame: From baseline to 4 weeks after final treatment). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Oct 2026; AzTrials last refreshed its copy on 26 Oct 2026.